Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 - MarketsandMarkets

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 - MarketsandMarkets
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017
Published May 31, 2013
313 pages — Published May 31, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Japan, China, India, South Korea, Malaysia, Indonesia, Australia, New Zealand, and Rest of Asia) to provide in-depth information on the Asia-Pacific scenario.

Asia-Pacific Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90

  
Source:
Document ID
PH 2004
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Contents

1 Introduction (Page No. - 27)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. - 35)

3 Market Overview (Page No. - 40)
3.1 Introduction
3.2 Definition Of Radiopharmaceuticals
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand
For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts The Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.4.3.3 Cyclotron-Based Production
3.4.3.4 Neurological Applications
3.4.4 Threat
3.4.4.1 Japanese Reactors Inefficient To Compensate The Domestic Nuclear Demand
3.5 Winning Imperatives
3.5.1 Investments On New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu-Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Fukushima Nuclear Disaster
3.7 Opal - A Sustainable Solution For Global Crisis In Mo-99 Supply
3.8 Regulatory Affairs
3.8.1 Japan
3.8.1.1 The Pharmaceuticals And Medical Devices Agency (PMDA, Sogo-Kiko)
3.8.2 China
3.8.2.1 China Food And Drug Administration (CFDA) & Office Of Administrative Protection
For Pharmaceuticals(OOAP)
3.8.3 India
3.8.3.1 Board Of Radiation & Isotope Technology (BRIT)
3.8.4 South Korea
3.8.4.1 Korea Institute Of Nuclear Safety (KINS) And Korea Institute Of Nuclear Nonproliferation
And Control(KINAC)
3.8.5 Malaysia
3.8.5.1 Atomic Energy Licensing Board (AELB)
3.8.6 Indonesia
3.8.6.1 Nuclear Energy Regulatory Agency (BAPETEN)
3.8.7 Australia & New Zealand
3.8.7.1 The Australian And New Zealand Society Of Nuclear Medicine (ANZSNM)
3.8.8 Roa
3.8.8.1 Dost (Philippines) & Crpns (Singapore)
3.9 Market Share Analysis
3.9.1 Radiopharmaceuticals Market
3.9.2 Enriched Stable Isotope Market

4 Asia-Pacific Radiopharmaceuticals Market, By Isotope (Page No. - 61)
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Sustainable Supply Of Technetium
4.2.2.2 Thallium-201 (TL-201)

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" May 31, 2013. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/Asia-Pacific-Nuclear-Medicine-Radiopharmaceuticals-Stable-Isotopes-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Deuterium-C-13-Forecast-to-2017-2144-137>
  
APA:
MarketsandMarkets. (2013). Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 May 31, 2013. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/Asia-Pacific-Nuclear-Medicine-Radiopharmaceuticals-Stable-Isotopes-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Deuterium-C-13-Forecast-to-2017-2144-137>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.